Patents by Inventor John D. Maynard

John D. Maynard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140235972
    Abstract: Embodiments of the present invention provide an apparatus suitable for determining properties of in vivo tissue from spectral information collected from the tissue. An illumination system provides light at a plurality of broadband ranges, which are communicated to an optical probe. The optical probe receives light from the illumination system and transmits it to in vivo tissue, and receives light diffusely reflected in response to the broadband light, emitted from the in vivo tissue by fluorescence thereof in response to the broadband light, or a combination thereof. The optical probe communicates the light to a spectrograph which produces a signal representative of the spectral properties of the light. An analysis system determines a property of the in vivo tissue from the spectral properties. A calibration device mounts such that it is periodically in optical communication with the optical probe.
    Type: Application
    Filed: February 15, 2013
    Publication date: August 21, 2014
    Inventors: Robert D. Johnson, Marwood Neal Ediger, John D. Maynard
  • Patent number: 8676283
    Abstract: A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual is disclosed. A portion of the skin of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can illuminate the skin and detect responsive light over a time that spans a plurality of cardiac cycles of the individual, which can, as an example, help mitigate the effects of time-varying signals such as those due to hemoglobin. The invention can also determine the amount of light to be directed to the skin, for example by controlling the time that a light source is energized. The amount of illumination light can be determined from a skin reflectance characteristic such as pigmentation or melanin in the skin.
    Type: Grant
    Filed: December 26, 2007
    Date of Patent: March 18, 2014
    Assignee: VeraLight, Inc.
    Inventors: Nathaniel Matter, Marwood Neal Ediger, John D Maynard
  • Publication number: 20130317328
    Abstract: Methods and apparatuses for the determination of an attribute of the tissue of an individual use non-invasive Raman spectroscopy. For example, the alcohol concentration in the blood or tissue of an individual can be determined. A portion of the tissue is illuminated with light, which propagates into the tissue where it is Raman scattered. The Raman scattered light is detected and can be combined with a model relating Raman spectra to alcohol concentration to determine the alcohol concentration in the blood or tissue. Correction techniques can reduce determination errors due to detection of light other than that from Raman scattering from the alcohol in the tissue. Other biologic information can be used with the Raman spectral properties to aid in the determination of alcohol concentration, for example age, height, weight, medical history and his/her family, ethnicity, skin melanin content, or a combination thereof.
    Type: Application
    Filed: July 17, 2013
    Publication date: November 28, 2013
    Inventors: Trent D. Ridder, Rob Johnson, Russell Abbink, John D. Maynard
  • Patent number: 8581697
    Abstract: Methods and apparatuses for the determination of an attribute of the tissue of an individual use non-invasive Raman spectroscopy. For example, the alcohol concentration in the blood or tissue of an individual can be determined non-invasively. A portion of the tissue is illuminated with light, the light propagates into the tissue where it is Raman scattered within the tissue. The Raman scattered light is then detected and can be combined with a model relating Raman spectra to alcohol concentration in order to determine the alcohol concentration in the blood or tissue of the individual. Correction techniques can be used to reduce determination errors due to detection of light other than that from Raman scattering from the alcohol in the tissue.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: November 12, 2013
    Assignee: TruTouch Technologies Inc.
    Inventors: Trent D Ridder, Rob Johnson, Russell Abbink, John D Maynard
  • Patent number: 8515506
    Abstract: Methods and apparatuses for the determination of an attribute of the tissue of an individual use non-invasive Raman spectroscopy. For example, the alcohol concentration in the blood or tissue of an individual can be determined non-invasively. A portion of the tissue is illuminated with light, the light propagates into the tissue where it is Raman scattered within the tissue. The Raman scattered light is then detected and can be combined with a model relating Raman spectra to alcohol concentration in order to determine the alcohol concentration in the blood or tissue of the individual. Correction techniques can be used to reduce determination errors due to detection of light other than that from Raman scattering from the alcohol in the tissue.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: August 20, 2013
    Assignee: TruTouch Technologies, Inc.
    Inventors: Trent D Ridder, Rob Johnson, Russell Abbink, John D Maynard
  • Publication number: 20120283530
    Abstract: Coronary artery calcification (CAC) occurs at an earlier age in diabetes and is a risk factor for coronary artery disease (CAD) in subjects with or without diabetes. One postulated mechanism for the increased CAC is the accelerated accumulation of advanced glycation end products (AGEs) in the vasculature. As certain collagen AGEs fluoresce, skin intrinsic fluorescence (SIF) can act as a novel maker of collagen AGEs levels. The present invention provides methods and apparatuses for detecting SIF that can be a useful marker of CAD risk and a therapeutic target.
    Type: Application
    Filed: November 17, 2010
    Publication date: November 8, 2012
    Inventors: John D. Maynard, Nathaniel Matter, Baqiyyah Conway, Trevor Orchard
  • Publication number: 20120283531
    Abstract: The present invention provides methods and apparatuses for determining a measure of a tissue state in an individual. Light emitted by tissue of the individual due to fluorescence of a chemical with the tissue detected. The invention can comprise measuring the fluorescence lifetime in either time-domain or frequency domain modes. The invention can also comprise a variety of models relating fluorescence to a measure of tissue state, for example, multivariate models can be developed that relate lifetime trends of one or more constituents to increasing propensity to diabetes and pre-diabetes. Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state.
    Type: Application
    Filed: July 6, 2012
    Publication date: November 8, 2012
    Inventors: John D. Maynard, Marwood Neal Ediger
  • Patent number: 8238993
    Abstract: A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can comprise measuring the fluorescence lifetime in either time-domain or frequency domain modes. The invention can also comprise a variety of models relating fluorescence to a measure of tissue state, including a variety of methods for generating such models. For example, multivariate models can be developed that relate lifetime trends of one or more constituents to increasing propensity to diabetes and pre-diabetes.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: August 7, 2012
    Assignee: VeraLight, Inc.
    Inventors: John D Maynard, Marwood Neal Ediger
  • Publication number: 20120179010
    Abstract: Embodiments of the present invention provide an apparatus suitable for determining properties of in vivo tissue. An illumination system communicates light at a plurality of broadband ranges to an optical probe, which can comprise a flexible probe. Light homogenizers and mode scramblers can be employed in some embodiments. The optical probe can physically contact the tissue, or can be maintained separate from the tissue. The optical probe receives light from the illumination system and transmits it to tissue, and receives light diffusely reflected in response to the broadband light, emitted from the in vivo tissue by fluorescence thereof in response to the broadband light, or a combination thereof. The optical probe can communicate the light to a spectrograph which produces a signal representative of the spectral properties of the light. An analysis system determines a property of the in vivo tissue from the spectral properties.
    Type: Application
    Filed: January 5, 2012
    Publication date: July 12, 2012
    Inventors: John D. Maynard, Marwood Neal Ediger, Robert D. Johnson, M. Ries Robinson
  • Publication number: 20120078075
    Abstract: The present invention provides a method of determining disease state in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical in the tissue responsive to the excitation light is detected. The HbA1c or FPG measurement of the individual (or other secondary indication of disease state) can also be determined. A model combining the tissue fluorescence and one or more of the secondary indications can be used to determine the disease state of the individual. In some embodiments, the tissue fluorescence can be used as an initial screen, and the combination with secondary indications only made for those individuals for whom the fluorescence screen indicates an increased likelihood of disease.
    Type: Application
    Filed: December 5, 2011
    Publication date: March 29, 2012
    Inventors: John D. Maynard, Edward Hull
  • Patent number: 8140147
    Abstract: Embodiments of the present invention provide an apparatus with a flexible probe suitable for determining properties of in vivo tissue from spectral information collected from various tissue sites. An illumination system provides light at a plurality of broadband ranges, which are communicated to a flexible optical probe. Light homogenizers and mode scramblers can be employed to improve the performance in some embodiments. The optical probe in some embodiments physically contacts the tissue, and in some embodiments does not physically contact the tissue. The optical probe receives light from the illumination system and transmits it to tissue, and receives light diffusely reflected in response to the broadband light, emitted from the in vivo tissue by fluorescence thereof in response to the broadband light, or a combination thereof. The optical probe can communicate the light to a spectrograph which produces a signal representative of the spectral properties of the light.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: March 20, 2012
    Assignee: VeraLight, Inc.
    Inventors: John D Maynard, Marwood Neal Ediger, Robert D Johnson, Mark Ries Robinson
  • Publication number: 20120065484
    Abstract: A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can comprise various light excitation and detection configurations. The invention also can comprise correction techniques that reduce determination errors due to detection of light other than that from fluorescence of a chemical in the tissue. Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state. The invention also comprises apparatuses suitable for carrying out the method.
    Type: Application
    Filed: November 9, 2011
    Publication date: March 15, 2012
    Inventors: Edward L. Hull, Marwood Neal Ediger, Christopher D. Brown, John D. Maynard, Robert D. Johnson
  • Patent number: 8131332
    Abstract: Embodiments of the present invention provide an apparatus suitable for determining properties of in vivo tissue from spectral information collected from various tissue sites. An illumination system provides light at a plurality of broadband ranges, which are communicated to an optical probe. The optical probe can be a flexible probe in some embodiments, allowing ease of application. Light homogenizers and mode scramblers can be employed to improve the performance in some embodiments. The optical probe in some embodiments physically contacts the tissue, and in some embodiments does not physically contact the tissue. The optical probe receives light from the illumination system and transmits it to tissue, and receives light diffusely reflected in response to the broadband light, emitted from the in vivo tissue by fluorescence thereof in response to the broadband light, or a combination thereof.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: March 6, 2012
    Assignee: VeraLight, Inc.
    Inventors: John D Maynard, Marwood Neal Ediger, Robert D Johnson, Mark Ries Robinson
  • Patent number: 8121671
    Abstract: A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can comprise single wavelength excitation light, scanning of excitation light (illuminating the tissue at a plurality of wavelengths), detection at a single wavelength, scanning of detection wavelengths (detecting emitted light at a plurality of wavelengths), and combinations thereof. The invention also can comprise correction techniques that reduce determination errors due to detection of light other than that from fluorescence of a chemical in the tissue.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: February 21, 2012
    Assignee: VeraLight, Inc.
    Inventors: Edward L. Hull, Marwood Neal Ediger, Christopher D. Brown, John D. Maynard, Robert D. Johnson
  • Patent number: 8078243
    Abstract: A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can comprise single wavelength excitation light, scanning of excitation light (illuminating the tissue at a plurality of wavelengths), detection at a single wavelength, scanning of detection wavelengths (detecting emitted light at a plurality of wavelengths), and combinations thereof. The invention also can comprise correction techniques that reduce determination errors due to detection of light other than that from fluorescence of a chemical in the tissue.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: December 13, 2011
    Assignee: VeraLight, Inc.
    Inventors: Marwood Neal Ediger, John D Maynard, Robert D Johnson, Edward L Hull, Christopher D Brown
  • Patent number: 7889349
    Abstract: The present invention provides improved methods and apparatuses for accurate measurements using interferometers. A functional relationship between the optical path difference and time is determined from a reference signal from an interferometer. The times at which the interferometer had specific optical path differences can be determined from the functional relationship. Those times can then be used to select times at which the spectroscopic signal from the interferometer was produced at the specific optical path differences. The invention can be applied, as examples, to maintain instrument calibration, and to transfer or compare calibrations or measurements across different interferometers.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: February 15, 2011
    Assignee: TruTouch Technologies, Inc.
    Inventors: Trent Ridder, Ben ver Steeg, Michael Haass, John D. Maynard, Zachary Benz
  • Patent number: 7616123
    Abstract: The present invention relates generally to non-invasive methods and apparatuses for determining analyte properties of a subject and identity characteristics of a subject. Embodiments of the present invention provide analyte property determination and identity determination or verification from the same spectroscopic information, making unauthorized use or misleading results less likely that in systems that include separate analyte and identity determinations. The invention can be used to control and monitor individuals accessing controlled environments.
    Type: Grant
    Filed: September 5, 2006
    Date of Patent: November 10, 2009
    Assignee: TruTouch Technologies, Inc.
    Inventors: Trent Ridder, Ben ver Steeg, James McNally, John D. Maynard, Russell E. Abbink
  • Publication number: 20090234204
    Abstract: Methods and apparatuses for the determination of an attribute of the tissue of an individual use non-invasive Raman spectroscopy. For example, the alcohol concentration in the blood or tissue of an individual can be determined non-invasively. A portion of the tissue is illuminated with light, the light propagates into the tissue where it is Raman scattered within the tissue. The Raman scattered light is then detected and can be combined with a model relating Raman spectra to alcohol concentration in order to determine the alcohol concentration in the blood or tissue of the individual. Correction techniques can be used to reduce determination errors due to detection of light other than that from Raman scattering from the alcohol in the tissue.
    Type: Application
    Filed: April 23, 2008
    Publication date: September 17, 2009
    Inventors: Trent Ridder, Rob Johnson, Russell Abbink, John D. Maynard
  • Patent number: 7446878
    Abstract: The present invention provides methods and apparatuses that can improve measurement accuracy in interferometers. The invention provides methods for determining digital compensation filters that measure a frequency response or responses to be compensated, and then determining a filter target response from the inverse of the frequency response or responses. A digital compensation filter can be determined from the filter target response using a discrete sum of cosines with a phase argument. The invention also allows other desired filter responses to be integrated into the filter target response before determining the digital compensation filter.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: November 4, 2008
    Assignee: TruTouch Technologies, Inc.
    Inventors: Trent Ridder, Ben ver Steeg, John D. Maynard, Zachary Benz
  • Publication number: 20080208018
    Abstract: Methods and apparatuses for the determination of an attribute of the tissue of an individual use non-invasive Raman spectroscopy. For example, the alcohol concentration in the blood or tissue of an individual can be determined non-invasively. A portion of the tissue is illuminated with light, the light propagates into the tissue where it is Raman scattered within the tissue. The Raman scattered light is then detected and can be combined with a model relating Raman spectra to alcohol concentration in order to determine the alcohol concentration in the blood or tissue of the individual. Correction techniques can be used to reduce determination errors due to detection of light other than that from Raman scattering from the alcohol in the tissue.
    Type: Application
    Filed: April 23, 2008
    Publication date: August 28, 2008
    Inventors: Trent Ridder, Rob Johnson, Russell Abbink, John D. Maynard